IBIO iBio, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IBIO matters now
iBio, Inc. (IBIO) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.51 with +0.00% on the session and $23.8M in market capitalization; recent performance reads 1-month +12.67% and YTD -12.44%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-7.7M, and EPS of $-0.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -83.1%.
The latest indexable market news headline is "iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $5.00; recent insider activity includes Stoner Elizabeth filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.61
P/S
88.95
EV/EBITDA
0.71
DCF Value
$0.25
FCF Yield
-83.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-160.0%
Operating Margin
-7985.3%
Net Margin
-9202.0%
ROE
-53.9%
ROA
-32.2%
ROIC
-30.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-7.7M | $-0.06 |
| Q2 2026 | $0.00 | $-9.0M | $-0.09 |
| Q1 2026 | $100.0K | $-5.7M | $-0.11 |
| Q4 2025 | $200.0K | $-5.2M | $-0.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.00
Target (Median)
$5.00
Target Range
$5.00 - $5.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.27
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.